Edgewise Therapeutics (NASDAQ:EWTX) Upgraded by HC Wainwright to Strong-Buy Rating

Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by investment analysts at HC Wainwright to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q1 2026 earnings at ($0.43) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.60) EPS.

EWTX has been the subject of several other research reports. JPMorgan Chase & Co. increased their price target on Edgewise Therapeutics from $33.00 to $34.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Royal Bank Of Canada upped their target price on Edgewise Therapeutics from $49.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Evercore restated an “outperform” rating and set a $45.00 price target on shares of Edgewise Therapeutics in a report on Thursday. Wall Street Zen downgraded shares of Edgewise Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Stifel Nicolaus set a $25.00 price objective on shares of Edgewise Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Edgewise Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.36.

Edgewise Therapeutics Stock Performance

Shares of NASDAQ:EWTX opened at $30.44 on Thursday. The firm has a market cap of $3.22 billion, a PE ratio of -18.67 and a beta of 0.27. The firm’s fifty day moving average is $27.62 and its 200-day moving average is $21.17. Edgewise Therapeutics has a 52 week low of $10.60 and a 52 week high of $31.82.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). Sell-side analysts forecast that Edgewise Therapeutics will post -1.45 EPS for the current year.

Insider Activity

In other news, Director Badreddin Edris sold 115,471 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the completion of the sale, the director owned 19,820 shares of the company’s stock, valued at $583,500.80. This trade represents a 85.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Bessemer Group Inc. grew its holdings in Edgewise Therapeutics by 1,170.3% in the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock worth $38,000 after purchasing an additional 2,165 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Edgewise Therapeutics during the second quarter valued at about $45,000. Jones Financial Companies Lllp bought a new position in shares of Edgewise Therapeutics during the 1st quarter worth about $47,000. Seven Fleet Capital Management LP acquired a new stake in shares of Edgewise Therapeutics in the 4th quarter valued at about $50,000. Finally, Steward Partners Investment Advisory LLC increased its position in Edgewise Therapeutics by 23.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $71,000 after buying an additional 550 shares in the last quarter.

Edgewise Therapeutics News Roundup

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.